Pharmicell (005690) — Cash Flow-to-Debt Ratio
Pharmicell (005690) has a Cash Flow-to-Debt Ratio of 0.45x as of September 2025, meaning its operating cash flow of ₩8.78 Billion could theoretically repay 0% of its total liabilities (₩19.60 Billion) in one year. Explore Pharmicell (005690) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pharmicell Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for Pharmicell across 13 annual periods. Also explore total assets of Pharmicell for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Pharmicell (2010–2024)
Year-by-year debt coverage analysis for Pharmicell. For market capitalisation and broader financial context, see 005690 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.27x | ₩3.50 Billion | ₩12.83 Billion | ▼ -72.0% |
| 2023 | 0.97x | ₩11.81 Billion | ₩12.12 Billion | ▲ +306.2% |
| 2022 | 0.24x | ₩7.91 Billion | ₩32.98 Billion | ▲ +240.0% |
| 2021 | -0.17x | ₩-5.22 Billion | ₩30.46 Billion | ▼ -124.1% |
| 2020 | 0.71x | ₩8.98 Billion | ₩12.64 Billion | ▲ +11152.1% |
| 2019 | -0.01x | ₩-75.50 Million | ₩11.75 Billion | ▼ -102.2% |
| 2018 | 0.29x | ₩3.40 Billion | ₩11.63 Billion | ▲ +213.2% |
| 2017 | -0.26x | ₩-2.01 Billion | ₩7.76 Billion | ▼ -292.5% |
| 2016 | 0.13x | ₩988.97 Million | ₩7.36 Billion | ▲ +184.7% |
| 2013 | -0.16x | ₩-2.69 Billion | ₩16.95 Billion | ▲ +53.4% |
| 2012 | -0.34x | ₩-11.87 Billion | ₩34.84 Billion | ▲ +61.4% |
| 2011 | -0.88x | ₩-16.17 Billion | ₩18.33 Billion | ▼ -107.9% |
| 2010 | -0.42x | ₩-8.41 Billion | ₩19.84 Billion | — |